Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN AND FAMOTIDINE vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis,Management of ankylosing spondylitis,Dysmenorrhea,Mild to moderate pain,Reduction of fever,Off-label: Migraine, gout, acute musculoskeletal pain
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (Cr Cl <10 m L/min).
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Famotidine is minimally metabolized in the liver (30-35%) via oxidative pathways; the remainder is excreted unchanged in urine.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Ibuprofen: >99% bound to albumin (mostly). Famotidine: 15-20% bound to plasma proteins (albumin).
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding and limited tissue distribution). Famotidine: 1.1-1.4 L/kg (suggests extensive extravascular distribution).
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Ibuprofen: Oral: 80-100% (well absorbed with food causing slight delay). Famotidine: Oral: 40-50% (first-pass metabolism; reduced with food).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Contraindicated if Cr Cl < 30 m L/min. For Cr Cl 30-49 m L/min, reduce famotidine dose by 50% (not possible with fixed combination; use alternative therapy).
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No specific dose adjustment for Child-Pugh A or B; avoid in severe hepatic impairment (Child-Pugh C) due to ibuprofen component.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not established for combination; ibuprofen 5-10 mg/kg/dose (max 400 mg) q6-8h as separate agent; famotidine 0.5 mg/kg/dose (max 20 mg) q12h for pediatric use.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Start at lowest effective dose; monitor renal function; avoid if Cr Cl < 30 m L/min; increased risk of GI bleeding and renal impairment.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events. Gastrointestinal risk: Serious GI adverse events including bleeding, ulceration, and perforation. Renal toxicity: Monitor renal function. Hepatic effects: Elevation of liver enzymes. Anaphylactoid reactions: Bronchospasm in aspirin-sensitive asthma. Hypertension: Can worsen blood pressure control. Fluid retention and edema.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
History of allergic reaction to ibuprofen, famotidine, or any other NSAID. History of aspirin-sensitive asthma. Coronary artery bypass graft (CABG) surgery. Active peptic ulcer disease or GI bleeding. Advanced renal disease. Pregnancy at 30 weeks gestation and later (risk of premature closure of ductus arteriosus).
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid alcohol; increases GI bleeding risk. No other significant food interactions. Take with food or milk to reduce gastric irritation.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low risk, but limited data. Second trimester: Ibuprofen use is linked to fetal renal dysfunction and oligohydramnios; famotidine appears safe. Third trimester: Ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension; famotidine has no known fetal risks.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Ibuprofen: Excretion into breast milk is low (M/P ratio 0.007-0.24); considered compatible with breastfeeding. Famotidine: Excreted in breast milk (M/P ratio approximately 0.25-0.71); infant exposure is low; generally acceptable with caution. Combined use: Limited data; monitor infant for gastrointestinal effects.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Ibuprofen: No standard dose adjustment; avoid in third trimester. Famotidine: No dose adjustment required. Combined product: Avoid in third trimester; use lowest effective dose and shortest duration in first/second trimester.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Ibuprofen and famotidine combination tablet (Duexis) is used for osteoarthritis and rheumatoid arthritis to reduce GI ulcer risk. Do not exceed 800 mg ibuprofen per dose or 3200 mg per day. Famotidine component provides gastric protection; additional acid suppression not needed. Avoid in advanced renal disease, active GI bleeding, or COX-2 inhibitor allergy. Monitor renal function, BP, and signs of GI bleeding. Dual COX/5-LOX inhibition by ibuprofen raises cardiovascular thrombotic risk; use lowest effective dose.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take with food or milk to reduce stomach upset.,Do not take more than 3 tablets per day (each tablet contains 800 mg ibuprofen).,May cause drowsiness or dizziness; avoid driving if affected.,Report black/tarry stools, vomiting blood, chest pain, or leg swelling immediately.,Avoid alcohol and other NSAIDs (e.g., aspirin, naproxen) while taking this medication.,Inform all healthcare providers you are taking this drug, especially before surgery.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN AND FAMOTIDINE vs ALFENTA, answered by our medical review team.
IBUPROFEN AND FAMOTIDINE is a NSAID that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN AND FAMOTIDINE and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN AND FAMOTIDINE is: One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN AND FAMOTIDINE and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN AND FAMOTIDINE is classified as Category D/X. First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low ri. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.